Literature DB >> 18317915

Non-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice.

Maya Guglin1, Marcos Garcia, Michael J Yarnoz, Anne B Curtis.   

Abstract

Many treatment modalities have been developed over the years for the management of atrial fibrillation (AF). While they are still considered the first line of treatment for suppression of AF, antiarrhythmics often lead to treatment failure, complications and undesired consequences. Pulmonary vein ablation is an invasive procedure which is not always curative. Recently, there have been a variety of studies reporting the potential antiarrhythmic effects of various nonantiarrhythmic agents. This paper aims to provide a comprehensive review of the findings reported thus far about the antiarrhythmic effects of agents which are not antiarrhythmic drugs themselves, but which have been found to offer promise in the prevention and treatment of AF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317915     DOI: 10.1007/s10840-008-9204-7

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  87 in total

1.  Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker.

Authors:  Guy Amit; Amos Katz; Shikma Bar-On; Harel Gilutz; Avraham Wagshal; Reuven Ilia; Yaakov Henkin
Journal:  Clin Cardiol       Date:  2006-06       Impact factor: 2.882

2.  Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein.

Authors:  David Amar; Hao Zhang; Paul M Heerdt; Bernard Park; Martin Fleisher; Howard T Thaler
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

3.  Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo.

Authors:  P E McEwan; G A Gray; L Sherry; D J Webb; C J Kenyon
Journal:  Circulation       Date:  1998-12-15       Impact factor: 29.690

4.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

5.  Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

Authors:  J Biollaz; H R Brunner; I Gavras; B Waeber; H Gavras
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

6.  Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.

Authors:  C Michael White; Jeffrey Kluger; Kirkeith Lertsburapa; Osman Faheem; Craig I Coleman
Journal:  Eur J Cardiothorac Surg       Date:  2007-03-12       Impact factor: 4.191

7.  Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.

Authors:  Giuseppe Patti; Massimo Chello; Dario Candura; Vincenzo Pasceri; Andrea D'Ambrosio; Elvio Covino; Germano Di Sciascio
Journal:  Circulation       Date:  2006-09-25       Impact factor: 29.690

8.  Effects of lisinopril in patients with heart failure and chronic atrial fibrillation.

Authors:  M P Van Den Berg; H J Crijns; D J Van Veldhuisen; N Griep; P J De Kam; K I Lie
Journal:  J Card Fail       Date:  1995-12       Impact factor: 5.712

9.  Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death.

Authors:  Hong D Xiao; Sebastien Fuchs; Duncan J Campbell; William Lewis; Samuel C Dudley; Vijaykumar S Kasi; Brian D Hoit; George Keshelava; Hui Zhao; Mario R Capecchi; Kenneth E Bernstein
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

View more
  1 in total

1.  American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association.

Authors:  N A Mark Estes; Ralph L Sacco; Sana M Al-Khatib; Patrick T Ellinor; Judy Bezanson; Alvaro Alonso; Charles Antzelevitch; Randall G Brockman; Peng-Sheng Chen; Sumeet S Chugh; Anne B Curtis; John P DiMarco; Kenneth A Ellenbogen; Andrew E Epstein; Michael D Ezekowitz; Pierre Fayad; Brian F Gage; Alan S Go; Mark A Hlatky; Elaine M Hylek; Michael Jerosch-Herold; Marvin A Konstam; Richard Lee; Douglas L Packer; Sunny S Po; Eric N Prystowsky; Susan Redline; Yves Rosenberg; David R Van Wagoner; Kathryn A Wood; Lixia Yue; Emelia J Benjamin
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.